Download PDF
CC BY-NC-ND 4.0 · Avicenna J Med 2020; 10(04): 198-207
DOI: 10.4103/ajm.ajm_17_20
Original Article

Aspirin dosage for the prevention of graft occlusion in people undergoing coronary surgery: a systematic review and meta-analysis

Fares Alahdab
Evidence-based Practice Center, Mayo Clinic, Rochester, Michigan,USA
,
Ruba Zuhri Yafi
Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic
,
Abdelkader Chaar
Department of Medicine, Yale New Haven Hospital, New Haven, Connecticut, USA
,
Ali Alrstom
Department of Medicine, Damascus University, Almwasat Hospital, Damascus, Syrian Arab Republic
,
Muayad Alzuabi
Department of Neurology, Medical University of South Carolina, Charleston, South Carolina
,
Omar Alhalabi
Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
,
Somar Hasan
Department of Ophthalmology, Jena University Hospital, Jena, Germany
,
Mahmoud Mallak
Children’s University Hospital
,
Mohamad Luay Jazayerli
Faculty of Medicine, University of Damascus, Damascus, Syrian Arab Republic
,
Qusay Haydour
Department of Internal Medicine, Cleveland Clinic Akron General, Akron
,
Mohamad Alkhouli
Department of Cardiovascular Medicine, Mayo Clinic
,
Wedad Alfarkh
Department of Pathology, Baylor College of Medicine
,
Mohammad Hassan Murad
Mayo Evidence-based Practice Center (EPC), Mayo Clinic, Rochester, Michigan, USA
› Author Affiliations
Subject Editor: Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Background: Aspirin is almost always used after coronary artery bypass graft (CABG) surgery; however, it is unclear what optimal dose should be prescribed. In this systematic review, we evaluated the effects of high versus low-dose aspirin in patients after CABG. Methods: A comprehensive database search was conducted in several databases from date of inception until February 2018. There were no language restrictions. We included studies that compared different doses of aspirin in patients that had undergone CABG surgery. We included studies that evaluated patient-important outcomes (mortality, cardiovascular events, and gastrointestinal bleeding); and if not reported, we collected data on the surrogate outcome thromboxane B2 (TXB2). We collected relevant data and performed a meta-analysis. Results: We identified 5903 references, and after two levels of screening by two independent reviewers, we included three randomized controlled trials in the meta-analysis with a total number of 122 participants. Mean age of trial participants was 65.63 years, and 88.68% were male. We planned to analyze all possible clinical outcomes, including mortality, recurrence, and hospitalization. However, no clinical outcomes are reported by the literature. The surrogate biochemical outcome of serum TXB2 was the only outcome reported by the eligible studies. High-dose aspirin (162–325 mg once daily) achieved better suppression of TXB2 than low-dose aspirin (75–100 mg once daily) (mean difference [MD], 2.00ng/mL, 95% confidence interval [CI]: 0.72–3.32; participants = 122; studies = 3; I2 = 0%). Conclusions: We found no clinical trials addressing any of the clinical outcomes of interest. High-dose aspirin was superior to low-dose aspirin in suppressing platelet function, a surrogate outcome. Trials evaluating clinical and patient-important outcomes are needed to better inform medical practice and fill this gap in clinical knowledge.

Keywords

Aspirin - atherosclerosis - coronary artery bypass graft - myocardial infarction - review - systematic review


Publication History

Article published online:
04 August 2021

© 2020. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Cooper GJ, Underwood MJ, Deverall PB. Arterial and venous conduits for coronary artery bypass. A current review. Eur J Cardiothorac Surg 1996; 10: 129-40
    CrossrefPubMedGoogle Scholar
  • 2 Bourassa MG. Long-term vein graft patency. Curr Opin Cardiol 1994; 9: 685-91
    CrossrefPubMedGoogle Scholar
  • 3 FitzGibbon GM, Kafka HP, Leach AJ, Burton JR. Interventions for coronary stenosis—a Canadian experience of 30 revolutionary years. Canadian J Cardiol 1996; 12: 893-900
    Google Scholar
  • 4 Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson Jr TB, Lorenz TJ. et al PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: A randomized controlled trial. JAMA 2005; 294: 2446-54
    CrossrefPubMedGoogle Scholar
  • 5 Gluckman TJ, McLean RC, Schulman SP, Kickler TS, Shapiro EP, Conte JV. et al. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol 2011; 57: 1069-77
    CrossrefPubMedGoogle Scholar
  • 6 Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG. et al VA Cooperative Study Group #207/297/364. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: Results from a department of veterans affairs cooperative study. J Am Coll Cardiol 2004; 44: 2149-56
    CrossrefPubMedGoogle Scholar
  • 7 Halabi AR, Alexander JH, Shaw LK, Lorenz TJ, Liao L, Kong DF. et al. Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. Am J Cardiol 2005; 96: 1254-9
    CrossrefPubMedGoogle Scholar
  • 8 Khot UN, Friedman DT, Pettersson G, Smedira NG, Li J, Ellis SG. Radial artery bypass grafts have an increased occurrence of angiographically severe stenosis and occlusion compared with left internal mammary arteries and saphenous vein grafts. Circulation 2004; 109: 2086-91
    CrossrefPubMedGoogle Scholar
  • 9 Shroyer AL, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E. et al Veterans Affairs Randomized On/Off Bypass (ROOBY) Study Group. On-pump versus off-pump coronary-artery bypass surgery. N Engl J Med 2009; 361: 1827-37
    CrossrefPubMedGoogle Scholar
  • 10 Widimsky P, Straka Z, Stros P, Jirasek K, Dvorak J, Votava J. et al. One-year coronary bypass graft patency: A randomized comparison between off-pump and on-pump surgery angiographic results of the PRAGUE-4 trial. Circulation 2004; 110: 3418-23
    CrossrefPubMedGoogle Scholar
  • 11 Cohn LH. Cardiac Surgery in the Adult. New York: McGraw-Hill Medical; 2008
    Google Scholar
  • 12 Harskamp RE, Vassiliades TA, Mehta RH, de Winter RJ, Lopes RD, Xian Y. et al. Comparative effectiveness of hybrid coronary revascularization vs. coronary artery bypass grafting. J Am Coll Surg 2015; 221: 326-34.e1
    CrossrefPubMedGoogle Scholar
  • 13 Panoulas VF, Colombo A, Margonato A, Maisano F. Hybrid coronary revascularization: Promising, but yet to take off. J Am Coll Cardiol 2015; 65: 85-97
    CrossrefPubMedGoogle Scholar
  • 14 Shannon J, Colombo A, Alfieri O. Do hybrid procedures have proven clinical utility and are they the wave of the future?: Hybrid procedures have proven clinical utility and are the wave of the future. Circulation 2012; 125: 2492-503 discussion 2503
    CrossrefPubMedGoogle Scholar
  • 15 Modrau IS, Holm NR, Mæng M, Bøtker HE, Christiansen EH, Kristensen SD. et al Hybrid Coronary Revascularization Study Group. One-year clinical and angiographic results of hybrid coronary revascularization. J Thorac Cardiovasc Surg 2015; 150: 1181-6
    CrossrefPubMedGoogle Scholar
  • 16 Farooq V, Serruys PW, Bourantas C, Vranckx P, Diletti R, Garcia Garcia HM. et al. Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial. Eur Heart J 2012; 33: 3105-13
    CrossrefPubMedGoogle Scholar
  • 17 Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 1991; 83: 1526-33
    CrossrefPubMedGoogle Scholar
  • 18 Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG. et al American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; Society of Cardiovascular Anesthesiologists; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58: e123-210
    CrossrefPubMedGoogle Scholar
  • 19 Gukop P, Gutman N, Bilkhu R, Karapanagiotidis GT. Who might benefit from early aspirin after coronary artery surgery?. Interact Cardiovasc Thorac Surg 2014; 19: 505-11
    CrossrefPubMedGoogle Scholar
  • 20 Karzai W, Priebe HJ. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2003; 348: 1057-9 author reply 1057-9
    CrossrefPubMedGoogle Scholar
  • 21 Mangano DT. Aspirin and mortality from coronary bypass surgery, Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 2002; 347: 1309-17
    CrossrefPubMedGoogle Scholar
  • 22 Patel JH, Stoner JA, Owora A, Mathew ST, Thadani U. Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients. Am J Cardiol 2009; 103: 1687-93
    CrossrefPubMedGoogle Scholar
  • 23 Stein PD, Schünemann HJ, Dalen JE, Gutterman D. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 600-8S
    CrossrefPubMedGoogle Scholar
  • 24 Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T. et al. Long-term graft patency (3 years) after coronary artery surgery. Effects of aspirin: Results of a VA cooperative study. Circulation 1994; 89: 1138-43
    CrossrefPubMedGoogle Scholar
  • 25 Brown J, Lethaby A, Maxwell H, Wawrzyniak AJ, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2008; CD000535
    PubMedGoogle Scholar
  • 26 Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KAA. et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 10: 930-42
    Google Scholar
  • 27 Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL. et al Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 1682-7
    CrossrefPubMedGoogle Scholar
  • 28 Brambilla M, Parolari A, Camera M, Colli S, Eligini S, Centenaro C. et al. Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery. Thromb Haemost 2010; 103: 516-24
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Cornelissen J, Kirtland S, Lim E, Goddard M, Bellm S, Sheridan K. et al. Biological efficacy of low against medium dose aspirin regimen after coronary surgery: Analysis of platelet function. Thromb Haemost 2006; 95: 476-82
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6: e1000097
    CrossrefPubMedGoogle Scholar
  • 31 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org. [Last accessed on 2019 Nov 15]
    Google Scholar
  • 32 Review Manager (RevMan). Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014
  • 33 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60
    CrossrefPubMedGoogle Scholar
  • 34 Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S. editors Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org. [Last accessed on 2019 Nov 15]
    Google Scholar
  • 35 Paikin JS, Hirsh J, Ginsberg JS, Weitz JI, Chan NC, Whitlock RP. et al. Once versus twice daily aspirin after coronary bypass surgery: A randomized trial. J Thromb Haemost 2017; 15: 889-96
    CrossrefPubMedGoogle Scholar
  • 36 Paikin JS, Eikelboom JW, Whitlock RP, Ginsberg JS, Weitz GPare JI, Hirsh J. Randomized trial to examine the effect of ASA dose or ASA dosing frequency on ASA resistance after coronary artery bypass graft surgery. Eur Heart J 2013; 34: P234
    CrossrefGoogle Scholar
  • 37 Paikin JS, Hirsh J, Ginsberg JS, Weitz JI, Chan NC, Whitlock RP. et al. Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: A pilot randomized controlled trial. J Thromb Haemost 2015; 13: 448-56
    CrossrefPubMedGoogle Scholar
  • 38 Ivert T, Dalén M, Ander C, Stålesen R, Näsman P, Lordkipanidzé M. et al. Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid. Thromb Res 2017; 149: 64-9
    CrossrefPubMedGoogle Scholar
  • 39 Dobler CC, Morgan RL, Falck-Ytter Y, Montori VM, Murad MH. Assessing the validity of surrogate endpoints in the context of a controversy about the measurement of effectiveness of hepatitis C virus treatment. BMJ Evid Based Med 2018; 23: 50-3
    CrossrefPubMedGoogle Scholar
  • 40 McLean RC, Nazarian SM, Gluckman TJ, Schulman SP, Thiemann DR, Shapiro EP. et al. Relative importance of patient, procedural and anatomic risk factors for early vein graft thrombosis after coronary artery bypass graft surgery. J Cardiovasc Surg (Torino) 2011; 52: 877-85
    PubMedGoogle Scholar
  • 41 Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-83
    CrossrefPubMedGoogle Scholar
  • 42 Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P. et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: e637-68S
    CrossrefPubMedGoogle Scholar
  • 43 Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. 2. Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159-68
    CrossrefPubMedGoogle Scholar
  • 44 Fremes SE, Levinton C, Naylor CD, Chen E, Christakis GT, Goldman BS. Optimal antithrombotic therapy following aortocoronary bypass: A meta-analysis. Eur J Cardiothorac Surg 1993; 7: 169-80
    CrossrefPubMedGoogle Scholar
  • 45 Henderson WG, Goldman S, Copeland JG, Moritz TE, Harker LA. Antiplatelet or anticoagulant therapy after coronary artery bypass surgery. A meta-analysis of clinical trials. Ann Intern Med 1989; 111: 743-50
    CrossrefPubMedGoogle Scholar
  • 46 Lim E, Ali Z, Ali A, Routledge T, Edmonds L, Altman DG. et al. Indirect comparison meta-analysis of aspirin therapy after coronary surgery. BMJ 2003; 327: 1309
    CrossrefPubMedGoogle Scholar